Thus, PHT1 is a crucial target for therapeutic intervention in lupus and its functional and structural characterization is important to further elucidate its molecular position and in silico design of compounds that can block PHT1 activity and/or recruitment of TASL. The gene discussed is TASL; the disease is systemic lupus erythematosus.